http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ironwood Highlights Breadth of Gout Research to be Presented at the 2017 ACR/ARHP Annual Meeting
-
Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call
-
Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017
-
Ironwood Pharmaceuticals Announces Leadership Change
-
Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
-
Ironwood Pharma (IRWD) Announces FDA Approval of DUZALLO for Treatment of Hyperuricemia in Patients with Uncontrolled Gout
-
Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout
-
Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update
-
Ironwood Pharmaceuticals to Host Second Quarter 2017 Investor Update Call
-
Ironwood Pharma (IRWD) says IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease Met Primary Endpoint
-
Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease
-
Ironwood Pharmaceuticals to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
-
Ironwood Pharmaceuticals to Present at the Jefferies Healthcare Conference
-
Ironwood Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference
-
Ironwood Pharma (IRWD) Presents Data Further Elucidating Linaclotide's Effect on Pain at DDW
-
Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide’s Effect on Pain at Digestive Disease Week® 2017
-
Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update
-
Ironwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and IW-1701 at Digestive Disease Week® 2017
-
Ironwood Pharmaceuticals to Host First Quarter 2017 Investor Update Call
-
Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5)
-
Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer
-
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
-
Ironwood Pharmaceuticals Showcases Progress Delivering Innovative Medicines to Patients and Building a Top-Performing Commercial Biotech at R&D Day 2017
-
Ironwood Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference
-
Ironwood Pharmaceuticals to Host R&D Day on March 9, 2017
-
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
-
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2016 Investor Update Call
-
Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
-
Ironwood Pharmaceuticals (IRWD), Allergan (AGN) Gains FDA Approval for 72 mcg Dose of LINZESS
-
U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation
-
Ironwood Pharma (IRWD) to Detail Strong Execution Strategy at JPMorgan Conference
-
Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech
-
Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors
-
Ironwood Pharma (IRWD) Says FDA Accepts DUZALLO NDA
-
Ironwood Announces New Drug Application for DUZALLO™ (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review
-
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
-
Ironwood (IRWD), Allergan (AGN) Announce Phase IIb Data for Linaclotide Colonic Release-1 (CR1) in IBS-C; Plan to Advance to Phase III
-
Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
-
Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS
-
Ironwood Pharma (IRWD) LINZESS Approved in Japan for Adults with IBS-C
-
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C
-
Ironwood Pharma (IRWD) Announces Presentation of Additional Data from ZURAMPIC Phase 3s
-
Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of Rheumatology 2016 Annual Meeting
-
Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
-
Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update
-
Ironwood Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference
-
Ironwood Highlights Breadth of Gout Research with Presentations at the American College of Rheumatology 2016 Annual Meeting
-
Ironwood Pharmaceuticals to Host Third Quarter 2016 Investor Update Call
-
Nine in Ten Physicians Agree Target Goal for Gout Is Imperative, Yet Half of Patients Fail to Reach It, New Survey Shows
-
Ironwood Announces U.S. Availability of ZURAMPIC® (lesinurad) 200 mg Tablets for Patients with Uncontrolled Gout

